CKD-COVID19_RCT_group_1_6_months_postdose_3
Networks
-
Variables
-
Population
CKD-COVID19 - RCT group 1
The population is composed of patients in Ontario at least 18 years old with stage 3b-5 or end stage chronic kidney disease (CKD). Participants are part of a four-arm parallel-group randomized control trial (RCT) of Pfizer-BioNTech versus MODERNA COVID-19 vaccine. This population recieves two doses of the Pfizer-BioNTech vaccine and the Pfizer-BioNTech vaccine again for the third dose.
Data Collection Event
CKD-COVID19 - RCT group 1 - 6 months post-dose 3
Blood samples are collected
Information is collected about demographics, comorbidities, medications, laboratory values, and the history of clinic visits and hospital admissions from the Ontario Renal Reporting System (ORRS) or supplemented by the medical record where required.